Chase Therapeutics raised Series A-1 equity financing from The Brain Trust Accelerator Fund II in November 2017 to support Phase 1 clinical trial and related drug development activities.
In September 2018, the company received Series A-2 financing from Revolutions Rise of the Rest Seed Fund and the Brain Trust Accelerator Fund II to conduct Phase 2 clinical trials of both CtC413 and CTC-501 as well as to continue development of related bioassay products.
